On May 12, 2025, President Trump issued an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” directing HHS to communicate most-favored-nation, or MFN, price targets to pharmaceutical manufacturers and, if manufacturers do not make significant progress toward MFN pricing, to pursue rulemaking to impose such pricing across Medicare, Medicaid, and commercial markets.
All entries for: Adlai Nortye Ltd.
April 10, 2026
Adlai Nortye Ltd.
Neutral Outlook
Alameda, CA
1,001-5,000 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. The IRA established the Medicare Drug Price Negotiation Program, under which the Centers for Medicare & Medicaid Services, or CMS, is authorized to negotiate maximum fair prices, or MFPs, for certain high-expenditure, single-source drugs without generic or biosimilar competition.
Disease Area: Oncology
Drug Type: Small Molecule